INT125947

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2005
Last Reported 2009
Negated 2
Speculated 0
Reported most in Body
Documents 57
Total Number 57
Disease Relevance 23.69
Pain Relevance 17.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Adora2b) plasma membrane (Adora2b) signal transducer activity (Adora2b)
Anatomy Link Frequency
NG108-15 4
macrophages 3
vasculature 2
lung 2
hematopoietic cells 2
Adora2b (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 3483 100.00 Very High Very High Very High
agonist 2944 100.00 Very High Very High Very High
Central nervous system 73 99.20 Very High Very High Very High
Inflammation 909 98.40 Very High Very High Very High
bradykinin 22 98.16 Very High Very High Very High
ischemia 1171 97.88 Very High Very High Very High
Potency 494 97.60 Very High Very High Very High
Inflammatory response 41 97.48 Very High Very High Very High
cytokine 156 97.08 Very High Very High Very High
antagonist 672 96.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Targeted Disruption 178 99.84 Very High Very High Very High
Glioma 15 99.72 Very High Very High Very High
Neuroblastoma 60 99.54 Very High Very High Very High
Disease 228 99.44 Very High Very High Very High
Pheochromocytoma 15 99.40 Very High Very High Very High
Increased Venous Pressure Under Development 221 99.00 Very High Very High Very High
Vasculitis 36 98.76 Very High Very High Very High
Cv Unclassified Under Development 1203 97.88 Very High Very High Very High
INFLAMMATION 835 97.88 Very High Very High Very High
Alzheimer's Dementia 15 97.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
5,000 nM) was the most potent of the series, and it was confirmed to be a full agonist in a functional assay based on the measurement of its capacity to modulate cAMP levels in CHO cells expressing hA2B AR (Fig. 2).
Gene_expression (expressing) of A2B associated with agonist
1) Confidence 0.75 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.11
B through cullin-1 (Cul-1) deneddylation, they found a dose-dependent deneddylation of Cul-1 mediated by signaling through the A2BAR, suggesting that extracellular accumulation of adenosine and signaling through the A2BAR suppresses NF?
Gene_expression (signaling) of A2BAR associated with adenocard
2) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.55 Pain Relevance 0.39
The authors found highest expressional levels of the A2BAR in the vasculature and on macrophages.
Gene_expression (levels) of A2BAR in vasculature
3) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.87 Pain Relevance 0.43
The membranes were then incubated in 1:3,000 HRP-donkey anti-goat Ig for A2BAR detection (Santa Cruz).
Gene_expression (detection) of A2BAR
4) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0 Pain Relevance 0
After having shown that selective inhibition of the A2BAR attenuates renal protection by IP, we next pursued a potential therapeutic role of a specific A2BAR agonist (BAY 60–6583).
Gene_expression (protection) of A2BAR associated with agonist
5) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.48 Pain Relevance 0.36
B through cullin-1 (Cul-1) deneddylation, they found a dose-dependent deneddylation of Cul-1 mediated by signaling through the A2BAR, suggesting that extracellular accumulation of adenosine and signaling through the A2BAR suppresses NF?
Gene_expression (suppresses) of A2BAR associated with adenocard
6) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.63 Pain Relevance 0.37
In addition, genetic deletion of the A2BAR was associated with low-grade vascular inflammation, augmentation of pro-inflammatory cytokines such as TNF-?
Gene_expression (deletion) of A2BAR associated with inflammation, vasculitis and cytokine
7) Confidence 0.67 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.84 Pain Relevance 0.44
1.97, hA2AKi /hA2B EC50?
Gene_expression (/) of A2B
8) Confidence 0.65 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.08 Pain Relevance 0.36
Substitution at the paraposition of the phenyl ring with a halogen atom led to a two- to fourfold loss of A2B AR activity in comparison with the unsubstituted phenyl derivative 7 (EC50 hA2B?
Gene_expression (activity) of A2B
9) Confidence 0.65 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.18
Similar results were achieved introducing at the N6-position of 42 an ethyl group (EC50 hA2B?
Gene_expression (achieved) of A2B
10) Confidence 0.65 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.09 Pain Relevance 0.33
128 nM) and an improved binding profile in comparison with NECA and (S)-PHP-NECA in activating A2B AR, (hA1Ki /hA2B EC50?
Gene_expression (/) of A2B
11) Confidence 0.65 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.08 Pain Relevance 0.35
The same behaviour has been observed by introducing functions with reverse electronic effects, such as the 4-methoxy group (12, EC50 hA2B?
Gene_expression (introducing) of A2B
12) Confidence 0.65 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.19
These studies provide genetic evidence that even though the A2AAR, A2BAR or A3AR are expressed on cardiac tissues [11], [18], they do not mediate the heart-rate slowing effects of adenosine.


Gene_expression (expressed) of A2BAR in heart associated with adenocard
13) Confidence 0.64 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2727950 Disease Relevance 0.15 Pain Relevance 0.35
Taken together, these studies reveal for the first time, to our knowledge, a selective reno-vascular expression of the A2BAR within the kidneys.


Gene_expression (expression) of A2BAR
14) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.23 Pain Relevance 0.04
Bone marrow chimeric A2BAR mice expressing the A2BAR on the tissues but not on their hematopoietic cells (A2BAR?
Neg (not) Gene_expression (expressing) of A2BAR in hematopoietic cells
15) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.48 Pain Relevance 0.33
Finally, the use of a reporter mouse model and studies in bone marrow A2BAR chimera helped to pinpoint the source of A2BAR protection to the reno-vasculature.
Gene_expression (source) of A2BAR in vasculature
16) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.55 Pain Relevance 0.34
Bone marrow chimeric A2BAR mice expressing the A2BAR on the tissues but not on their hematopoietic cells (A2BAR?
Neg (not) Gene_expression (expressing) of A2BAR in hematopoietic cells
17) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.48 Pain Relevance 0.33
On the basis of the above studies showing induction of the renal A2BAR with preconditioning, we were interested to define, which tissues express the A2BAR within the kidneys.
Gene_expression (express) of A2BAR
18) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.18 Pain Relevance 0
On the basis of these studies showing reno-vascular expression of the A2BAR and other studies showing myeloid A2BAR expression, particularly on macrophages [44], we studied the contribution of renal or hematopoietic A2BAR signaling to renal protection during ischemia or IP.
Gene_expression (expression) of A2BAR in macrophages associated with ischemia
19) Confidence 0.60 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.29 Pain Relevance 0.05
The compounds were also evaluated in a functional assay, measuring their capacity to modulate cAMP levels in CHO cells expressing hA2B AR receptors.
Gene_expression (expressing) of A2B
20) Confidence 0.58 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox